Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (NCT0197536)
This partially randomized phase II trial studies how well brentuximab vedotin (also known as SGN-035) or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
Monoclonal antibody-drug conjugates or ADCs, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Crizotinib and methotrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether brentuximab vedotin and combination chemotherapy is more effective than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.
This trial is sponsored by the National Cancer Institute (NCI). 
- Condition: Lymphoma
- Phase: II
- Estimated Enrollment: 140
- Start: November 2013
- Estimated Primary Completion: September 2020 (Final data collection date for primary outcome measure)
- Last verified: March 2015
Last Editorial review: July 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.